엔젠바이오

354200KOSDAQ

65.9 / 100

Reference Date: 2026-09-08

Financial Score24.5 / 40

News Sentiment21.4 / 25

Momentum6.0 / 20

Disclosure14.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 18.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

EnzenBio is a biotech company specializing in in vitro diagnostic medical devices and services using genomic analysis, liquid biopsy, and precision diagnostics. It leverages next-generation sequencing (NGS) and bioinformatics algorithms to detect mutations in cancer and genetic diseases, offering personalized treatment solutions.

Number of Employees

56people

Average Salary

61.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

0.59Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE

-33.54Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

7.51Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲152.0% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲14.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -59.2% (improving, 3yr)

Detailed News Sentiment

7 totalPositive 7Neutral 0Negative 0Average Sentiment Score 85.7

Positive
엔젠바이오, 인천세종병원과 GLP-1 맞춤치료 솔루션 개발 협력
엔젠바이오와 인천세종병원의 협력으로 GLP-1 맞춤치료 솔루션 개발이 진행되어 비만치료 효과와 안전성 향상 기대.
Positive
“GLP-1도 맞춤치료”…엔젠바이오, 치료·부작용 예측검사 만든다
엔젠바이오가 GLP-1 계열 비만치료제의 개인 맞춤형 검사 개발로 혁신적인 의료 솔루션 제공에 성공함.
Positive
엔젠바이오, ‘GLP-1 맞춤치료’ 시장 진출…치료반응·부작용 예측검...
엔젠바이오가 GLP-1 맞춤치료 솔루션 개발로 시장 진출을 선언하며 기술적 우위를 확보하고 있다.

Detailed Momentum

52-week position5.0Point

52w mid range (40%)

Current 1,499Won52-week high 2,63552-week low 737

1-month return0.0Point

1m -18.00% (strong drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

11 totalPositive 2Neutral 9Negative 0

Neutral[기재정정]투자설명서2026-09-07
Positive[기재정정]주요사항보고서(유상증자결정)2026-09-07
Neutral[발행조건확정]증권신고서(지분증권)2026-09-07
Positive유상증자최종발행가액확정2026-09-07
Neutral효력발생안내( 2026.8.20. 제출 증권신고서(지분증권) )2026-09-04